Compare LTRX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | BNR |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | China |
| Employees | 352 | N/A |
| Industry | Computer Communications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.3M | 233.6M |
| IPO Year | 2000 | 2020 |
| Metric | LTRX | BNR |
|---|---|---|
| Price | $5.76 | $20.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.17 | N/A |
| AVG Volume (30 Days) | ★ 460.6K | 64.5K |
| Earning Date | 02-05-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $118,294,000.00 | $75,749,382.00 |
| Revenue This Year | $4.59 | $136.32 |
| Revenue Next Year | $12.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $1.91 | $2.18 |
| 52 Week High | $6.75 | $24.18 |
| Indicator | LTRX | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 57.00 |
| Support Level | $5.62 | $19.49 |
| Resistance Level | $5.93 | $21.57 |
| Average True Range (ATR) | 0.37 | 1.89 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 44.60 | 59.13 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.